#### SPECIAL ARTICLE

# A Randomized, Controlled Trial of Financial Incentives for Smoking Cessation

Kevin G. Volpp, M.D., Ph.D., Andrea B. Troxel, Sc.D., Mark V. Pauly, Ph.D., Henry A. Glick, Ph.D., Andrea Puig, B.A., David A. Asch, M.D., M.B.A., Robert Galvin, M.D., M.B.A., Jingsan Zhu, M.B.A., Fei Wan, M.S., Jill DeGuzman, B.S., Elizabeth Corbett, M.L.S., Janet Weiner, M.P.H., and Janet Audrain-McGovern, Ph.D.

#### ABSTRACT

#### BACKGROUND

Smoking is the leading preventable cause of premature death in the United States. Previous studies of financial incentives for smoking cessation in work settings have not shown that such incentives have significant effects on cessation rates, but these studies have had limited power, and the incentives used may have been insufficient.

N FANDOME ZED

#### METHODS

We randomly assigned 878 employees of a multinational company based in the United States to receive information about smoking-cessation programs (442 employees) or to receive information about programs plus financial incentives (436 employees). The financial incentives were \$100 for completion of a smoking-cessation program, \$250 for cessation of smoking within 6 months after study enrollment, as confirmed by a biochemical test, and \$400 for abstinence for an additional 6 months after the initial cessation, as confirmed by a biochemical test. Individual participants were stratified according to work site, heavy or nonheavy smoking, and income. The primary end point was smoking cessation 9 or 12 months after enrollment, depending on whether initial cessation was reported at 3 or 6 months. Secondary end points were smoking cessation within the first 6 months after enrollment and rates of participation in and completion of smoking-cessation programs.

#### RESULTS

The incentive group had significantly higher rates of smoking cessation than did the information-only group 9 or 12 months after enrollment (14.7% vs. 5.0%, P<0.001) and 15 or 18 months after enrollment (9.4% vs. 3.6%, P<0.001). Incentive-group participants also had significantly higher rates of enrollment in a smoking-cessation program (15.4% vs. 5.4%, P<0.001), completion of a smoking-cessation program (10.8% vs. 2.5%, P<0.001), and smoking cessation within the first 6 months after enrollment (20.9% vs. 11.8%, P<0.001).

#### CONCLUSIONS

In this study of employees of one large company, financial incentives for smoking cessation significantly increased the rates of smoking cessation. (ClinicalTrials.gov number, NCT00128375.)

From the Center for Health Equity Research and Promotion, Philadelphia Veterans Affairs Medical Center (K.G.V.. D.A.A.); the Center for Health Incentives, Leonard Davis Institute of Health Economics (K.G.V., A.B.T., M.V.P., H.A.G., D.A.A., J.Z., J.D., J.W.), the Department of Health Care Management, the Wharton School (K.G.V., M.V.P., H.A.G., A.P., D.A.A.), and the Center for Clinical Epidemiology and Biostatistics and Department of Biostatistics and Epidemiology (A.B.T., F.W.), University of Pennsylvania; the Department of Medicine (K.G.V., H.A.G., D.A.A., J.Z., J.D., E.C.) and the Transdisciplinary Tobacco Use Research Center, Department of Psychiatry (J.A.-M.), University of Pennsylvania School of Medicine — all in Philadelphia; General Electric, Fairfield, CT (R.G.); and Yale University School of Medicine, New Haven, CT (R.G.). Address reprint requests to Dr. Volpp at the Division of General Internal Medicine and Department of Health Care Management, University of Pennsylvania School of Medicine and the Wharton School, 1232 Blockley Hall, 423 Guardian Dr., Philadelphia, PA 19104-6021, or at volpp70@wharton. upenn.edu.

N Engl J Med 2009;360:699-709. Copyright © 2009 Massachusetts Medical Society. MOKING REMAINS THE LEADING PREventable cause of premature death in the United States, accounting for approximately 438,000 deaths each year.¹ Seventy percent of smokers report that they want to quit,² but annually only 2 to 3% of smokers succeed.³,⁴ Although smoking-cessation programs and pharmacologic therapies have been associated with higher rates of cessation, rates of participation in such programs and use of such therapies are low.⁵,6

Work sites offer a promising venue for encouraging smoking cessation because employers are likely to bear many of the excess health care costs and productivity losses that are due to missed work among smokers. In addition, existing channels of communication can be used to reach smokers and reinforce healthful behavior choices. Previous studies have shown that providing smokers with financial incentives to stop smoking increases enrollment in smoking-cessation programs and short-term cessation rates,7-10 but the studies have not shown significant increases in long-term cessation rates. Similarly, studies of financial-incentive programs in work settings have not shown significant differences in long-term cessation rates,11 though the studies generally were limited by small sample sizes and weak financial incentives.

In this randomized, controlled trial involving employees at a large, multinational company based in the United States, we tested the effectiveness of a financial incentive of up to \$750 in improving long-term rates of smoking cessation.

## METHODS

# STUDY POPULATION

We recruited study participants from February 2005 through November 2006 among employees at company work sites throughout the United States. Potential participants were identified with the use of a survey that asked employees about their smoking habits, their use of other tobacco products, and their willingness to be contacted by researchers from the University of Pennsylvania about participation in a smoking-cessation study. These surveys were distributed through the firm's intranet and, at sites with high proportions of employees who did not have intranet access, through on-site recruiting. Employees were eligible to participate if they were at least 18 years of age and if they reported that they were currently smoking

five or more cigarettes per day. Employees were not included in the study if they were currently using tobacco products other than cigarettes or if they planned to leave the firm within 18 months. All participants were followed for at least 12 months; only those with a confirmed negative result within the first 12 months on a cotinine test, a test that is used for biochemical verification of self-reported abstinence, were followed for an additional 6 months.

### STUDY PROTOCOL

The protocol was approved by the institutional review board at the University of Pennsylvania, and all participants provided written informed consent before randomization. All study participants received information about community-based smoking-cessation resources within 20 miles of their work site, as well as the standard health benefits provided by the firm, such as coverage of physician visits and bupropion or other drugs prescribed to promote cessation of tobacco use. Participants in the incentive group were also informed that they would receive financial incentives for completion of a community-based smoking-cessation program (\$100); for smoking cessation, confirmed with the use of a cotinine test, within 6 months after study enrollment (\$250); and for continued abstinence for an additional 6 months after the initial cessation (\$400).

All participants were contacted 3 months after enrollment and asked whether they had stopped smoking. Participants who reported complete abstinence (not even a puff of a cigarette) for at least 7 days before being contacted were interviewed so that we could obtain a more extensive assessment of smoking behavior. Participants who did not report complete abstinence were recontacted 3 months later (i.e., 6 months after enrollment) for the full follow-up assessment. Six months after completing their first full interview (i.e., at 9 months for those who reported quitting at 3 months; at 12 months for those who were interviewed at 6 months), everyone was interviewed again. Participants who reported during any follow-up interview that they had stopped smoking were asked to provide a saliva or urine sample for confirmation of smoking cessation with the use of a cotinine test. Participants with negative results of cotinine tests at both the interview conducted at 3 or 6 months and the interview conducted at 9 or 12 months were also interviewed 12 months after completion of their initial full interview (i.e., at 15 or 18 months).

Participants received \$20 per interview for participating in telephone interviews at baseline, at 3 or 6 months, at 9 or 12 months, and at 15 or 18 months. After each interview, participants who reported that they had stopped smoking received \$25 for submitting a sample for biochemical verification of the cotinine level.

#### RANDOMIZATION PROCEDURES

Participants were randomly assigned to a study group after they provided informed consent. Randomization was performed in permuted blocks of four and was stratified according to work site, income (<200%, 200 to 500%, or >500% of the federal poverty level, which was \$9,800 for a single person and \$20,000 for a family of four in 2006), and heavy or nonheavy smoking (with heavy smoking defined as two or more packs of cigarettes per day). The randomized assignments were concealed until all eligibility criteria had been entered in an electronic tracking system; however, blinding could not be maintained after this point because of the nature of the intervention.

## ASSESSMENTS OF END POINTS

The primary end point was the participant's self-report of abstinence at both 3 and 9 months or at both 6 and 12 months after study enrollment. Abstinence was biochemically confirmed by a negative result of a cotinine test performed on a saliva or urine sample. Self-reported continuous abstinence from all tobacco products was defined as abstinence for a minimum of 7 days before the 3- or 6-month interview (point prevalence) and abstinence for the duration of the period from the 3- or 6-month interview to the 9- or 12-month interview (prevalence).

Secondary end points included enrollment in a smoking-cessation program; completion of a smoking-cessation program; rates of smoking cessation within 6 months after study enrollment; and rates of smoking cessation at 3, 9, and 15 months or 6, 12, and 18 months after study enrollment. Participants were classified as having completed the smoking-cessation program if they provided a certificate of completion from the sponsoring organization.

All follow-up assessments were conducted with


Table 1. Characteristics of the Study Participants.*			
Characteristic	Control Group (N = 442)	Incentive Group (N = 436)	
Mean age (yr)	44.4	45.5	
Male sex (%)	64.9	65.6	
Race or ethnic group (%)†			
White	89.3	91.5	
Black	5.2	4.4	
Hispanic	4.1	4.1	
Other	5.4	4.1	
Level of education (%)			
High school or lower	25.6	25.2	
Some college or completion of college	39.6	40.8	
Beyond college	34.8	33.9	
Income (%)			
<200% of the poverty level	1.6	1.8	
200-500% of the poverty level	34.6	32.1	
>500% of the poverty level	63.8	66.1	
Smoking habits			
Mean cigarettes per day (no.)	19.7	20.1	
Smoking >2 packs per day (%)	6.1	5.1	
Mean previous attempts to quit (no.)	6.7	5.7	
Stage of change (%)‡			
Precontemplation	15.6	15.1	
Contemplation	63.8	67.0	
Preparation	20.6	17.9	
Self-assessed health (%)			
Poor	2.0	1.2	
Fair	9.3	8.5	
Good	32.1	33.7	
Very good	45.9	42.7	
Excellent	10.6	14.0	
Fagerström score for nicotine dependence $(\%)$			
<6	68.1	66.5	
≥6	31.9	33.5	

<sup>\*</sup> There were no significant differences between the control and incentive groups for any of the variables listed.

<sup>†</sup> Race or ethnic group was self-reported. One participant in the control group did not report race or ethnic group and therefore was not included in the denominator for the percentages.

<sup>\$\</sup>displaystage of change refers to the smoker's readiness, at baseline, to quit, as defined by DiClemente et al. 16 and Prochaska et al. 17

<sup>§</sup> The Fagerström Test for Nicotine Dependence<sup>14</sup> has a range of 0 to 10, with higher scores indicating more nicotine dependence; a score of 6 or greater was used to classify participants as highly dependent on nicotine.<sup>15</sup>



the use of a telephone interview. Self-reported cessation was verified by saliva cotinine tests (with a cotinine level of <15 ng per milliliter considered to be an indication of smoking cessation)<sup>12</sup> or by urine cotinine tests (with a level of <2 ng per milliliter considered to be an indication of smoking cessation).<sup>13</sup> Urine cotinine tests were used only in the case of participants who were using nicotine-replacement therapy, in whom testing of anabasine and anatabine levels in the urine was performed. Participants who reported abstinence but who had saliva or urine cotinine levels above the cutoff points were classified as smokers. Participants who were lost to follow-up were classified as relapsed smokers.

The collection of samples was coordinated by the study staff in conjunction with the healthpromotion staff at the firm and, at small work sites that did not have onsite health facilities, through contract with Examination Management Services (Scottsdale, AZ). Participants' identities were confirmed and samples were analyzed at the Clinical Pharmacology Laboratory at the University of California, San Francisco.

## BASELINE VARIABLES

The pretreatment level of nicotine dependence was assessed according to the number of cigarettes smoked per day, the number of years of smoking, and the score on the Fagerström Test for Nicotine Dependence<sup>14</sup> (which has a range of 0 to 10, with higher scores indicating more nicotine dependence); participants with a score of 6 or greater were classified as highly dependent on nicotine.<sup>15</sup>

End Point	Control Group (N = 442)	Incentive Group (N = 436)	P Value
	no. (%)		
Enrollment in smoking-cessation program			
Participation in program	24 (5.4)	67 (15.4)	< 0.001
Completion of program	11 (2.5)	47 (10.8)	< 0.001
Smoking cessation at 3 or 6 mo			
Self-reported	62 (14.0)	102 (23.4)	<0.001
Confirmed	52 (11.8)	91 (20.9)	<0.001
No sample submitted	9 (2.0)	9 (2.1)	0.79
Positive sample submitted	1 (0.2)	2 (0.5)	0.56
Smoking cessation at 3 or 6 mo with continued abstinence through 9 or 12 mo			
Self-reported	27 (6.1)	66 (15.1)	0.002
Confirmed	22 (5.0)	64 (14.7)	< 0.001
No sample submitted	5 (1.1)	2 (0.5)	0.06
Positive sample submitted	0	0	
Self-reported relapse	21 (4.8)	21 (4.8)	0.96
Continued abstinence at 15 or 18 mo among participants who quit at 3 or 6 mo and remained abstinent through 9 or 12 mo	per my	t denie	
Self-reported	17 (3.8) they ?	47 (10.8)	< 0.001
Confirmed	16 (3.6)	41 (9.4)	< 0.001
No sample submitted	1 (0.2)	6 (1.4)	0.03
Positive sample submitted	0	0	
Self-reported relapse	3 (0.7)	12 (2.8)	0.02

<sup>\*</sup> Smoking cessation was confirmed by means of a negative result on a cotinine test.

We also collected information on income, work site, baseline health status, and interest in quitting, as measured by baseline readiness to stop smoking (i.e., the "stage of change," as defined by DiClemente et al.<sup>16</sup> and Prochaska et al.<sup>17</sup>).

## STATISTICAL ANALYSIS

The primary analysis was an unadjusted intention-to-treat analysis of the difference in biochemically confirmed cessation rates between the incentive and control groups at both 3 and 9 months or at both 6 and 12 months. The analysis was performed with the use of Pearson's chi-square test, or with the use of Fisher's exact test, if there were five or fewer participants per cell. We used a similar approach to estimate differences in rates of cessa-

tion within 6 months after enrollment; rates of enrollment in and completion of smoking-cessation programs; and cessation rates at 3, 9, and 15 months or 6, 12, and 18 months after study enrollment. Unadjusted odds ratios for cessation were estimated and were compared with odds ratios that were adjusted for the stratification variables (work site, degree of nicotine dependence, and income) as well as the set of baseline covariates shown in Table 1; variable-selection methods were not applied. The similarity of the study groups with respect to covariates at baseline was analyzed by the chi-square test for categorical variables and the Student's t-test or Wilcoxon rank-sum test for continuous variables, as appropriate.

Although subgroup analyses were not prespeci-

Variable	Odds Ratio (95% CI)	P Value
Unadjusted model		
Incentive group	3.28 (1.98–5.44)	< 0.001
Control group	1.00	
Model adjusted for stratification variables only		
Study group		< 0.001
Incentive	3.19 (1.91–5.30)	
Control	1.00	
Work site*		0.12
Smoking status†		0.15
Heavy	0.34 (0.08–1.45)	
Nonheavy	1.00	
Poverty level		0.02
>500% of the poverty level	0.96 (0.20–4.63)	
200–500% of the poverty level	0.43 (0.08–2.16)	
<200% of the poverty level	1.00	
Model adjusted for all variables:		
Study group		< 0.001
Incentive	3.16 (1.88–5.32)	
Control	1.00	
Work site*		0.20
Age		0.87
≥40 yr	1.05 (0.58–1.90)	
<40 yr	1.00	
Sex		0.39
Male	0.80 (0.48–1.33)	
Female	1.00	
Race		0.69
Black	1.02 (0.32–3.20)	
White	1.00	
Other	0.50 (0.10–2.44)	
Ethnic group	,	0.80
Hispanic	1.20 (0.30–4.88)	
Non-Hispanic	1.00	
Level of education		0.69
Beyond college	0.92 (0.49–1.74)	
College	0.78 (0.42–1.43)	
High school or less	1.00	
Poverty level		0.04
>500% of the poverty level	1.03 (0.18–5.79)	
200–500% of the poverty level	0.48 (0.08–2.75)	
<200% of the poverty level	1.00	

Table 3. (Continued.)			
Variable	Odds Ratio (95% CI)	P Value	
Smoking status†		0.20	
Heavy	0.38 (0.09–1.67)		
Nonheavy	1.00		
Previous attempts to stop smoking		0.09	
≥5 (top third)	2.00 (1.08–3.71)		
3 or 4 (middle third)	1.58 (0.81–3.06)		
1 or 2 (bottom third)	1.00		
Stage of change§		0.10	
Preparation	2.61 (1.02–6.62)		
Contemplation	1.64 (0.71–3.83)		
Precontemplation	1.00		
Self-reported health		0.37	
Excellent	1.85 (0.21–16.54)		
Very good	1.14 (0.13–9.66)		
Good	1.09 (0.13–9.37)		
Fair	0.58 (0.06–6.08)		
Poor	1.00		

<sup>\*</sup> Odds ratios for work-site groups are not reported, owing to the large number of sites included.

fied, we looked at cessation rates in subgroups that were defined by seven baseline variables: sex, income (<200%, 200 to 500%, and >500% of the federal poverty level), heavy smoking (≥2 packs per day) or nonheavy smoking, number of previous attempts to quit (0 to 2, 3 or 4, or  $\geq$ 5), stage of quitting as defined by Prochaska et al.17 (precontemplation, contemplation, or preparation), selfassessed health (poor, fair, good, very good, or excellent), and nicotine dependence as assessed by the score on the Fagerström Test for Nicotine Dependence (<6 or  $\ge6$ ). The homogeneity of the association (i.e., interaction) between the group assignment and cessation rates across subgroups was assessed with the use of the Cochran-Mantel-Haenszel test. Within each subgroup, rates of cessation in the incentive and control groups were compared with the use of chi-square tests.

Our power calculations were based on expected 12-month cessation rates of 3.0% in the control group and 9.4% in the incentive group. To have 80% power to show a difference between groups, with a 1% two-sided type I error, we needed to have 360 participants in each group; we increased

that number by 15%, to 425 in each group, to account for loss to follow-up resulting from expected employee turnover. No interim analyses were planned or conducted. All reported P values are two-sided and were not adjusted for multiple comparisons.

## RESULTS

Figure 1 shows the numbers of subjects who were screened and who participated in the study intervention and follow-up. Of the 1903 people who initially expressed interest in participating, 878 (46%) were enrolled; (436) participants were randomly assigned to the incentive group, and (442) to the control group. Demographic characteristics, smoking behavior, degree of nicotine dependence, readiness to quit, and health status were similar in the incentive and control groups (Table 1). Participants in both groups smoked approximately one pack of cigarettes per day, and approximately 5 to 6% of the participants were heavy smokers. The majority of the sample had incomes that were greater than 500% of the poverty level, and ap-

<sup>†</sup> Heavy smoking was defined as 40 cigarettes or more per day.

<sup>‡</sup> One study participant was not included in this analysis, owing to missing data on race or ethnic group.

 $<sup>\</sup>S$  Stage of change refers to the smoker's readiness to quit, as defined by DiClemente et al. 16 and Prochaska et al. 17




Figure 2. Rates of Smoking Cessation in Various Subgroups at 9 or 12 Months.

Stage of change refers to the smoker's readiness to quit, as defined by DiClemente et al.<sup>16</sup> and Prochaska et al.<sup>17</sup> The Fagerström Test for Nicotine Dependence<sup>14</sup> has a range of 0 to 10, with higher scores indicating greater nicotine dependence; a score of 6 or more was used to classify participants as highly dependent on nicotine.<sup>15</sup>

6(2=7/4=0) 24 6 mos.

proximately 90% of the participants were white. A similar number of participants in the incentive and control groups were lost to follow-up or withdrew in the first 6 months (66 and 59) participants, respectively; P=0.45) and through month 12 (56) and (47) respectively; P=0.25).

The 9-month or 12-month rate of cessation, as confirmed by cotinine testing, was 14.7% in the incentive group, as compared with 5.0% in the control group (P<0.001) (Table 2). In both the incentive group and the control group, very few of the participants who reported that they had quit smoking did not submit samples for testing (0.5% and 1.1%, respectively), and no participants who submitted samples had positive test results. The rate of participation in a smoking-cessation program was significantly higher in the incentive

group than in the control group (15.4% vs. 5.4%, P<0.001), and a significantly higher percentage of incentive-group participants completed a smoking-cessation program (10.8% vs. 2.5%, P<0.001). Members of the incentive group who participated in a smoking-cessation program had significantly higher rates of cessation than did members of the control group who participated in such a program (46.3% vs. 20.8%, P=0.03).

The cotinine-confirmed cessation rate within 6 months after study enrollment was 20.9% in the incentive group, as compared with 11.8% in the control group (P<0.001). The cessation rate at 15 or 18 months was 9.4% in the incentive group, as compared with 3.6% in the control group (P=0.001). Among participants who had not stopped smoking in the first 6 months — and

thus were ineligible for financial incentives — the cotinine-confirmed cessation rates were similar in the incentive and control groups (4.1% and 5.9%, respectively; P=0.29).

The odds ratios for quitting by 9 or 12 months (Table 3) were significantly higher in the incentive group than in the control group in the unadjusted model (odds ratio, 3.28; 95% confidence interval [CI], 1.98 to 5.44), in a logistic-regression model that adjusted for stratification variables only (odds ratio, 3.19; 95% CI, 1.91 to 5.30), and in a model that adjusted for all the variables included in Table 1 (odds ratio, 3.16; 95% CI, 1.88 to 5.32).

#### **EXPLORATORY SUBGROUP ANALYSES**

Figure 2 shows 9-month or 12-month cessation rates stratified according to subgroup. For all subgroups, members of the incentive group had higher cessation rates than members of the control group. None of the tests for interaction showed significant differences in this population; instead, the observed patterns showed a consistent effect of the intervention across numerous characteristics.

#### DISCUSSION

In this study of employees at a large corporation, rates of prolonged abstinence from smoking after 9 or 12 months of follow-up were 14.7% in the group that was eligible for financial incentives and 5.0% in the control group. Rates of prolonged abstinence at 15 or 18 months in the incentive group remained significantly higher than those in the control group.

A 2005 Cochrane Collaboration review of financial incentives for smoking cessation in workplace settings concluded that there was insufficient evidence that these incentives are effective.11 One reason for this finding may be that many previous studies were not designed with samples that were large enough to detect the differences we observed. A second reason may be that the incentives used in previous studies have generally been small (as little as \$10 in some of them). Studies have shown that financial-incentive programs are associated with an increased rate of smoking cessation in the short term, but the programs reported in these studies were not designed to focus on sustaining high rates over time.<sup>7,9</sup> The relationships of the size and structure of incentive payments to rates of smoking cessation remain important empirical questions that need to be addressed in future research. It is possible that larger — or smaller — payments by employers could be more cost-effective in improving smoking-cessation rates. The optimal design of incentive programs for smoking cessation is also an open question, since extension of the incentives beyond 12 months may result in higher cessation rates over a longer period.

The cotinine level, which we used for biochemical verification of 7-day abstinence, is considered to be the best biomarker of smoking cessation. Consistent with the recommendations of the Society for Research on Nicotine and Tobacco, our primary measure of self-reported cessation at both 9 or 12 months and 15 or 18 months was prolonged abstinence. Although prolonged abstinence can be biochemically verified only indirectly because of the limitations of the cotinine test, it is likely that the point prevalence is highly correlated with prolonged abstinence 6 months after short-term quitting was assessed.

To date, financial incentives within health care settings have been directed primarily toward providers, through Pay for Performance (P4P) programs. However, given that up to 40% of premature deaths in the United States are due to unhealthful behaviors such as smoking, poor dietary habits, and sedentary lifestyles,18 incentives directed toward patients rather than providers may have greater potential for changing health behaviors.19-21 One approach to encouraging smoking cessation would be to adjust health-insurance premiums on the basis of smoking status; however, targeted payments for smoking cessation have the advantage of being unbundled from health-insurance premiums and thus may be more salient to people, thereby having a greater influence on behavior.22

The financial benefit to employers of having their employees stop smoking is estimated to be about \$3,400 per year<sup>23</sup> as a result of increased productivity, decreased absenteeism, and a reduced incidence of illness. There is also strong evidence that employees prefer to work for firms that offer effective and attractive benefit programs.<sup>24</sup> However, few employers offer full coverage of smoking-cessation services or cessation programs in the workplace,<sup>8,25,26</sup> partly because a compelling "business case" for such coverage has not been made. Notably, neither the financial-incentive intervention nor the control intervention in our study

included the establishment of a smoking-cessation program; both interventions merely encouraged participants to use existing programs.

The literature on smoking cessation suggests that most relapses occur within the first month of cessation, that approximately 90% of relapses occur within the first 6 months,27 and that the likelihood of continuous abstinence over a 20-month period is about 95% for smokers who quit for 1 year or longer.12 Our finding of relapse rates between the 9- or 12-month visit and the 15- or 18-month visit (27.3% in the control group and 35.9% in the incentive group) that appear to be higher than those reported in the literature may suggest that relapse rates differ according to whether smoking cessation occurs in the presence or absence of incentives. However, since the relapse rates in both the incentive and control groups differ from those in the literature, and in view of the relatively small number of participants in our study who quit smoking, we cannot be confident that the relapse rates do in fact differ from those previously reported.

Because approximately 90% of the enrolled population was white and the participants had relatively high education and income levels, our study may have limited generalizability to employees with lower socioeconomic status than that of the participants in our study or to members of a minority racial or ethnic group. In addition, programs that are designed to change behavior may

have unintended consequences that we could not observe in our study. However, we think it is unlikely that substantial numbers of people would start smoking in order to be eligible for such incentive programs. Studies such as this one are subject to selection bias, in that smokers who voluntarily enroll in these programs may be more likely (whether they are assigned to the incentive group or the control group) to quit smoking; it is difficult to project how effective these programs would be in a population that included all employees within a given company.

In summary, this study shows that smokingcessation rates among company employees who were given both information about cessation programs and financial incentives to quit smoking were significantly higher than the rates among employees who were given program information but no financial incentives.

Supported by grants from the Centers for Disease Control and Prevention (RO1 DP000100-01 and RO1 DP001168-01) and from the Pennsylvania Department of Health, which specifically disclaims responsibility for any analyses, interpretations, or conclusions.

Dr. Volpp reports receiving lecture fees from Aetna and grant support from Aetna and Pfizer and owning equity in General Electric; Dr. Pauly, being a board member of Independent Health, owning equity in General Electric, receiving lecture fees from America's Health Insurance Plans, and receiving grant support from Merck and MedStar; Dr. Glick, owning equity in General Electric; and Dr. Galvin, owning equity in General Electric. No other potential conflict of interest relevant to this article was reported.

We thank Quincy Greene for his contributions to the analyses for this article and Donna Tomlinson, M.D., for assistance in implementing this study.

#### REFERENCES

- 1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004;291: 1238-45. [Errata, JAMA 2005;293:293-4, 298.]
- **2.** Cigarette smoking among adults United States, 2000. MMWR Morb Mortal Wkly Rep 2002;51:642-5.
- 3. Annual smoking-attributable mortality, years of potential life lost, and productivity losses United States, 1997–2001. MMWR Morb Mortal Wkly Rep 2005;54:625-8.
- **4.** Tobacco use among adults United States, 2005. MMWR Morb Mortal Wkly Rep 2006;55:1145-8.
- **5.** Zhu S, Melcer T, Sun J, Rosbrook B, Pierce JP. Smoking cessation with and without assistance: a population-based analysis. Am J Prev Med 2000;18:305-11.
- **6.** Fiore MC. US Public Health Service Clinical Practice Guideline: treating tobacco use and dependence. Respir Care 2000;45:1200-62.
- 7. Volpp KG, Gurmankin Levy A, Asch

- DA, et al. A randomized controlled trial of financial incentives for smoking cessation. Cancer Epidemiol Biomarkers Prev 2006; 15:12-8.
- **8.** Hennrikus DJ, Jeffery RW, Lando HA, et al. The SUCCESS project: the effect of program format and incentives on participation and cessation in worksite smoking cessation programs. Am J Public Health 2002;92:274-9.
- **9.** Donatelle RJ, Prows SL, Champeau D, Hudson D. Randomised controlled trial using social support and financial incentives for high risk pregnant smokers: Significant Other Supporter (SOS) program. Tob Control 2000;9:Suppl 3:III67-III69.
- 10. Donatelle RJ, Hudson D, Dobie S, Goodall A, Hunsberger M, Oswald K. Incentives in smoking cessation: status of the field and implications for research and practice with pregnant smokers. Nicotine Tob Res 2004;6:Suppl 2:S163-S179.

  11. Hey K, Perera R. Competitions and incentives for smoking cessation. Cochrane

- **12.** SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res 2002;4:149-59.
- **13.** Jacob P III, Hatsukami D, Severson H, Hall S, Yu L, Benowitz N. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 2002;11: 1668-73.
- **14.** Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991;86:1119-27.
- **15.** Westman EC, Behm FM, Simel DL, Rose JE. Smoking behavior on the first day of a quit attempt predicts long-term abstinence. Arch Intern Med 1997;157:335-40.
- **16.** DiClemente CC, Prochaska JO, Fairhurst SK, Velicer WF, Velasquez MM, Rossi JS. The process of smoking cessation: an analysis of precontemplation, contemplation, and preparation stages of change. J Consult Clin Psychol 1991;59:295-304.

Database Syst Rev 2005;2:CD004307.

- 17. Prochaska JO, DiClemente CC, Velicer WF, Rossi JS. Standardized, individualized, interactive, and personalized self-help programs for smoking cessation. Health Psychol 1993;12:399-405.
- **18.** Schroeder SA. Shattuck Lecture: We can do better improving the health of the American people. N Engl J Med 2007; 357:1221-8.
- **19.** Sindelar JL. Paying for performance: the power of incentives over habits. Health Econ 2008;17:449-51.
- **20.** Loewenstein G, Brennan T, Volpp KG. Asymmetric paternalism to improve health behaviors. JAMA 2007;298:2415-7.
- 21. Volpp KG, Pauly MV, Loewenstein G,

- Bangsberg D. P4P4P: an agenda for research on pay-for-performance for patients. Health Aff (Millwood) 2009;28:206-14.
- **22.** Thaler RH. Mental accounting and consumer choice. Marketing Sci 1985;4: 199-214.
- **23.** Annual smoking-attributable mortality, years of potential life lost, and economic costs United States, 1995–1999. MMWR Morb Mortal Wkly Rep 2002;51: 300-3.
- **24.** Pauly MV. Health benefits at work: an economic and political analysis of employment-based health insurance. Ann Arbor: University of Michigan Press, 2002.
- 25. Barbeau EM, Li Y, Sorenson G, Con-

- lan KM, Youngstrom R, Emmons K. Coverage of smoking cessation treatment by union health and welfare funds. Am J Public Health 2001;91:1412-5.
- **26.** Aakko E, Piasecki TM, Remington P, Fiore MC. Smoking cessation services offered by health insurance plans for Wisconsin state employees. WMJ 1999;98:
- **27.** Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004; 99:29-38.

Copyright © 2009 Massachusetts Medical Society.

#### POSTING PRESENTATIONS AT MEDICAL MEETINGS ON THE INTERNET

Posting an audio recording of an oral presentation at a medical meeting on the Internet, with selected slides from the presentation, will not be considered prior publication. This will allow students and physicians who are unable to attend the meeting to hear the presentation and view the slides. If there are any questions about this policy, authors should feel free to call the *Journal's* Editorial Offices.